Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Discovery of a novel class of orally active antifungal beta-1,3-D-glucan synthase inhibitors.

Walker SS, Xu Y, Triantafyllou I, Waldman MF, Mendrick C, Brown N, Mann P, Chau A, Patel R, Bauman N, Norris C, Antonacci B, Gurnani M, Cacciapuoti A, McNicholas PM, Wainhaus S, Herr RJ, Kuang R, Aslanian RG, Ting PC, Black TA.

Antimicrob Agents Chemother. 2011 Nov;55(11):5099-106. doi: 10.1128/AAC.00432-11. Epub 2011 Aug 15.

2.

Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.

Mann PA, McNicholas PM, Chau AS, Patel R, Mendrick C, Ullmann AJ, Cornely OA, Patino H, Black TA.

Antimicrob Agents Chemother. 2009 Dec;53(12):5026-34. doi: 10.1128/AAC.01031-09. Epub 2009 Sep 28.

3.

Clinical evaluation of the Sensititre YeastOne plate for testing susceptibility of filamentous fungi to posaconazole.

Patel R, Mendrick C, Knapp CC, Grist R, McNicholas PM.

J Clin Microbiol. 2007 Jun;45(6):2000-1. Epub 2007 Apr 11.

4.

Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection.

Cacciapuoti A, Halpern J, Mendrick C, Norris C, Patel R, Loebenberg D.

Antimicrob Agents Chemother. 2006 Jul;50(7):2587-90.

5.

In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.

Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, Loebenberg D, Black TA, McNicholas PM.

Antimicrob Agents Chemother. 2006 Jun;50(6):2009-15.

6.

Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles.

Chau AS, Mendrick CA, Sabatelli FJ, Loebenberg D, McNicholas PM.

Antimicrob Agents Chemother. 2004 Jun;48(6):2124-31.

7.

Changes in susceptibility to posaconazole in clinical isolates of Candida albicans.

Li X, Brown N, Chau AS, López-Ribot JL, Ruesga MT, Quindos G, Mendrick CA, Hare RS, Loebenberg D, DiDomenico B, McNicholas PM.

J Antimicrob Chemother. 2004 Jan;53(1):74-80. Epub 2003 Dec 4.

PMID:
14657086
8.

Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase.

Mann PA, Parmegiani RM, Wei SQ, Mendrick CA, Li X, Loebenberg D, DiDomenico B, Hare RS, Walker SS, McNicholas PM.

Antimicrob Agents Chemother. 2003 Feb;47(2):577-81.

9.

EmtA, a rRNA methyltransferase conferring high-level evernimicin resistance.

Mann PA, Xiong L, Mankin AS, Chau AS, Mendrick CA, Najarian DJ, Cramer CA, Loebenberg D, Coates E, Murgolo NJ, Aarestrup FM, Goering RV, Black TA, Hare RS, McNicholas PM.

Mol Microbiol. 2001 Sep;41(6):1349-56.

10.

Evernimicin (SCH27899) inhibits a novel ribosome target site: analysis of 23S ribosomal DNA mutants.

Adrian PV, Mendrick C, Loebenberg D, McNicholas P, Shaw KJ, Klugman KP, Hare RS, Black TA.

Antimicrob Agents Chemother. 2000 Nov;44(11):3101-6.

11.

In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida.

Cacciapuoti A, Loebenberg D, Corcoran E, Menzel F Jr, Moss EL Jr, Norris C, Michalski M, Raynor K, Halpern J, Mendrick C, Arnold B, Antonacci B, Parmegiani R, Yarosh-Tomaine T, Miller GH, Hare RS.

Antimicrob Agents Chemother. 2000 Aug;44(8):2017-22.

Supplemental Content

Loading ...
Support Center